Roberto Arrojo
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 8
- PARP inhibition in cancer therapy 3
- Cancer Treatment and Pharmacology 3
- HER2/EGFR in Cancer Research 3
-
- DNA Repair Mechanisms 2
- Glycosylation and Glycoproteins Research 2
- Cancer therapeutics and mechanisms 2
- Co-authors
- David M. Goldenberg (10 shared papers)Thomas M. Cardillo (10 shared papers)Robert M. Sharkey (7 shared papers)Chien‐Hsing Chang (5 shared papers)Preeti Trisal (2 shared papers)Donglin Liu (2 shared papers)Serengulam V. Govindan (6 shared papers)Edmund A. Rossi (2 shared papers)
- Journals
- Cancer Research (5 papers)Oncotarget (2 papers)Bioconjugate Chemistry (1 paper)Clinical Cancer Research (1 paper)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- United States
In The Last Decade
Roberto Arrojo
11 papers receiving 395 citations
Peers
Comparison fields: 5 of 36
- Oncology 289
- Radiology, Nuclear Medicine and Imaging 128
- Pulmonary and Respiratory Medicine 71
- Cancer Research 29
- Molecular Biology 119
Countries citing papers authored by Roberto Arrojo
This map shows the geographic impact of Roberto Arrojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Arrojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Arrojo more than expected).
Fields of papers citing papers by Roberto Arrojo
This network shows the impact of papers produced by Roberto Arrojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Arrojo. The network helps show where Roberto Arrojo may publish in the future.
Co-authors
The 13 scholars most cited alongside Roberto Arrojo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 217 | |
| 2 | 2017 | 102 | |
| 3 | 2020 | 35 | |
| 4 | 2013 | 28 | |
| 5 | 2024 | 11 | |
| 6 | 2010 | 4 | |
| 7 | 2010 | 4 | |
| 8 | 2012 | 4 | |
| 9 | 2016 | 2 | |
| 10 | 2016 | 1 | |
| 11 | 2015 | 1 |
About Roberto Arrojo
Roberto Arrojo is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Surgery, having authored 11 papers that have together received 409 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (4 papers), PARP inhibition in cancer therapy (3 papers), Cancer Treatment and Pharmacology (3 papers), Radiopharmaceutical Chemistry and Applications (3 papers), HER2/EGFR in Cancer Research (3 papers), DNA Repair Mechanisms (2 papers), Glycosylation and Glycoproteins Research (2 papers) and Cancer therapeutics and mechanisms (2 papers). The work is most often cited by research in Oncology (289 citations), Radiology, Nuclear Medicine and Imaging (128 citations), Pulmonary and Respiratory Medicine (71 citations), Cancer Research (29 citations) and Molecular Biology (119 citations). Roberto Arrojo has collaborated with scholars based in United States. Frequent co-authors include David M. Goldenberg, Thomas M. Cardillo, Robert M. Sharkey, Chien‐Hsing Chang, Preeti Trisal, Donglin Liu, Serengulam V. Govindan, Edmund A. Rossi, Diane L. Rossi and Sung-Ju Moon. Their work appears in journals such as Cancer Research, Oncotarget, Bioconjugate Chemistry, Clinical Cancer Research and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.